How have IGXT shares performed in 2024?

IntelGenx Technologies' stock was trading at $0.1381 at the beginning of 2024. Since then, IGXT shares have increased by 19.5% and is now trading at $0.1650. View the best growth stocks for 2024 here .

Are investors shorting IntelGenx Technologies?

IntelGenx Technologies saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 71,000 shares, an increase of 11,733.3% from the March 15th total of 600 shares. Based on an average daily volume of 213,700 shares, the days-to-cover ratio is presently 0.3 days. View IntelGenx Technologies' Short Interest .

How were IntelGenx Technologies' earnings last quarter?

IntelGenx Technologies Corp. (OTCMKTS:IGXT) announced its earnings results on Thursday, March, 21st. The company reported ($0.02) earnings per share (EPS) for the quarter. The company earned $0.43 million during the quarter.

What other stocks do shareholders of IntelGenx Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IntelGenx Technologies investors own include Cronos Group (CRON) , Zevra Therapeutics (KMPH) , Exelixis (EXEL) , SemiLEDs (LEDS) , New Residential Investment (NRZ) , Anavex Life Sciences (AVXL) , BioDelivery Sciences International (BDSI) , BIOLASE (BIOL) and Ocugen (OCGN) .

How do I buy shares of IntelGenx Technologies?

Shares of IGXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

OTCMKTS:IGXT

IntelGenx Technologies (IGXT) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free IGXT Stock Alerts

$0.17

-0.01 (-5.71%)

(As of 04/19/2024 ET)

Compare

Today's Range: $0.16
▼
$0.17
50-Day Range: $0.14
▼
$0.19
52-Week Range: $0.09
▼
$0.22

Volume: 53,282 shs
Average Volume: 92,385 shs
Market Capitalization: $28.82 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Earnings Financials Headlines SEC Filings Short Interest

Get IntelGenx Technologies alerts:

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About IntelGenx Technologies Stock (OTCMKTS:IGXT)

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 and INT0055/2021 are for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was incorporated in 1999 and is headquartered in Montreal, Canada.

IGXT Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IGXT Stock News Headlines

April 11, 2024 | americanbankingnews.com

IntelGenx Technologies Corp. (OTCMKTS:IGXT) Short Interest Update

April 8, 2024 | finance.yahoo.com

IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

April 8, 2024 | globenewswire.com

IntelGenx Announces First Parkinson's Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK' Clinical Trial

April 5, 2024 | globenewswire.com

IntelGenx Updates Status of Buprenorphine Buccal Film ANDA

March 23, 2024 | seekingalpha.com

IntelGenx Technologies Corp. (IGXT) Q4 2023 Earnings Call Transcript

March 22, 2024 | insidermonkey.com

IntelGenx Technologies Corp. (PNK:IGXT) Q4 2023 Earnings Call Transcript

March 21, 2024 | investorplace.com

IGXT Stock Earnings: Intelgenx Technologies Reported Results for Q4 2023

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

March 21, 2024 | globenewswire.com

IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results

March 16, 2024 | seekingalpha.com

IGXT IntelGenx Technologies Corp.

March 14, 2024 | globenewswire.com

IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 – Conference Call to Follow

March 11, 2024 | globenewswire.com

IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences

February 20, 2024 | finance.yahoo.com

UPDATE -- IntelGenx Launches Preferred Share Regulation A Offering

February 20, 2024 | globenewswire.com

UPDATE -- IntelGenx Launches Preferred Share Regulation A Offering

February 20, 2024 | globenewswire.com

IntelGenx Launches Preferred Share Regulation A Offering

February 19, 2024 | finance.yahoo.com

IntelGenx Technologies Corp. (IGXT)

February 5, 2024 | finance.yahoo.com

Studies Validate Advantages of Administering Drugs to Pets via IntelGenx’s VetaFilm® Platform

December 7, 2023 | morningstar.com

Intelgenx Technologies Corp IGXT

November 14, 2023 | finance.yahoo.com

IntelGenx Receives Approval to Conduct ’MONTPARK’ Montelukast VersaFilm® Phase 2 Clinical Trial in Patients with Parkinson's Disease

November 13, 2023 | finance.yahoo.com

IntelGenx Reminds Shareholders to Vote at Upcoming Special Meeting

November 10, 2023 | insidermonkey.com

IntelGenx Technologies Corp. (PNK:IGXT) Q3 2023 Earnings Call Transcript

November 9, 2023 | finance.yahoo.com

IntelGenx Reports Third Quarter 2023 Financial Results

November 6, 2023 | finance.yahoo.com

IntelGenx Announces Co-development and Commercialization of Cannabinoid-Infused VersaFilm® Products with Tilray

September 21, 2023 | finance.yahoo.com

IntelGenx Provides RIZAFILM® U.S. Commercialization Update

August 31, 2023 | finance.yahoo.com

IntelGenx Announces Closing of First Tranche of Non-Brokered Private Placement From Strategic Partner for Approximate Aggregate Gross Proceeds of US$3 Million (Including US$750,000 to be Received by the Company Once Shareholder Approvals Have Been Obtained)

August 16, 2023 | finanznachrichten.de

IntelGenx Technologies Corp.: IntelGenx Reports Second Quarter 2023 Financial Results

See More Headlines

Receive IGXT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IntelGenx Technologies and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/21/2024
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: OTCMKTS:IGXT
CUSIP: 45822R101
CIK: 1098880
Web: www.intelgenx.com
Phone: (514) 331-7440
Fax: 514-331-0436
Employees: 4
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($0.06)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-9,930,000.00
Net Margins: -955.44%
Pretax Margin: -955.44%
Return on Equity: N/A
Return on Assets: -128.18%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.41
Quick Ratio: 0.40

Sales & Book Value

Annual Sales: $1.04 million
Price / Sales: 27.71
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.07) per share
Price / Book: -2.36

Miscellaneous

Outstanding Shares: 174,660,000
Free Float: 101,214,000
Market Cap: $28.82 million
Optionable: Not Optionable
Beta: 2.43

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Mr. Dwight Gorham (Age 66)
Chief Executive Officer
Comp: $230.56k
Mr. Tommy Kenny J.D. (Age 37)
L.L.B., M.Sc., Senior VP & General Counsel
Comp: $152.62k
Ms. Nadine Paiement M.Sc. (Age 47)
Vice-Chair of Scientific Advisory Board and VP of Research & Development - IntelGenx Corp
Comp: $156.5k
Stephen Kilmer
Investor Relations Officer
Ms. Ingrid Zerbe (Age 70)
Corporate Secretary
Zenoz Nina Pourhassan
VP of Quality Operations of Subsidiary

Key Competitors

View All Competitors

IGXT Stock Analysis - Frequently Asked Questions

How have IGXT shares performed in 2024?: IntelGenx Technologies' stock was trading at $0.1381 at the beginning of 2024. Since then, IGXT shares have increased by 19.5% and is now trading at $0.1650.
View the best growth stocks for 2024 here.
Are investors shorting IntelGenx Technologies?: IntelGenx Technologies saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 71,000 shares, an increase of 11,733.3% from the March 15th total of 600 shares. Based on an average daily volume of 213,700 shares, the days-to-cover ratio is presently 0.3 days.
View IntelGenx Technologies' Short Interest.
How were IntelGenx Technologies' earnings last quarter?: IntelGenx Technologies Corp. (OTCMKTS:IGXT) announced its earnings results on Thursday, March, 21st. The company reported ($0.02) earnings per share (EPS) for the quarter. The company earned $0.43 million during the quarter.

What other stocks do shareholders of IntelGenx Technologies own?: Based on aggregate information from My MarketBeat watchlists, some companies that other IntelGenx Technologies investors own include Cronos Group (CRON), Zevra Therapeutics (KMPH), Exelixis (EXEL), SemiLEDs (LEDS), New Residential Investment (NRZ), Anavex Life Sciences (AVXL), BioDelivery Sciences International (BDSI), BIOLASE (BIOL) and Ocugen (OCGN).
How do I buy shares of IntelGenx Technologies?: Shares of IGXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:IGXT) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial